Xiaohuang Qudan decoction alleviates ANIT-induced cholestatic liver injury by inhibiting the JAK2/STAT3 pathway and regulating TH17/Treg

Abstract

Xiaohuang Qudan decoction (XHQDD) is a classical traditional Chinese medicine (TCM) formula widely used in the treatment of cholestatic liver injury. Despite its widespread use, the protective mechanism of XHQDD against cholestatic liver injury remains incompletely understood. The aim of this study was to investigate whether XHQDD mediates its beneficial effects by inhibiting the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway and regulating TH17/Treg balance. To this end, the researchers used Sprague-Dawley (SD) rats and established a cholestatic liver injury model by oral administration of alpha-naphthylisothiocyanate (ANIT). The experimental group was divided into six groups: Control (CON), ANIT, ursodeoxycholic acid (UDCA), XHQDD-low dose (XHQDD-L) group, XHQDD-medium dose (XHQDD-M) group, and XHQDD-high dose (XHQDD-H) groups. Then, after 7 d of treatment, various tests were performed to verify the results. Firstly, XHQDD and its drug-containing serum were analyzed by ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry (UPLC-MS/MS), and 14 blood-entry components were identified. Then, bile flow was monitored and found to be significantly reduced in the model group, which was significantly reversed in the UDCA and XHQDD groups. To further assess ANIT-induced liver injury, hematoxylin and eosin (H&E) and Sirius red staining, alongside transmission electron microscopy (TEM), were employed to observe liver tissues, revealing hepatocellular injury, cholestasis, and hepatic fibrotic changes. Serum inflammatory factors and liver injury indicators were assessed using enzyme-linked immunosorbent assay (ELISA), indicating an inflammatory state in ANIT-induced liver injury rats. The expression levels of JAK2/STAT3-related genes and proteins in liver and intestinal tissues were measured via quantitative reverse transcription polymerase chain reaction (qRT-PCR), immunohistochemistry, immunofluorescence (IF) staining, and Western blottting (WB) assays. These studies revealed that the inflammatory state of liver-injured rats was inextricably linked to the inflammatory cascade associated with the JAK2/STAT3 pathway and that XHQDD may exert anti-inflammatory efficacy by inhibiting the JAK2/STAT3 pathway. Flow cytometry was used to determine the percentage of T helper 17 (Th17)/regulatory T (Treg) cells in serum and hepatocytes, and it was further found that XHQDD was able to regulate Th17/Treg immune homeostasis in liver-injured rats. The findings suggest that XHQDD markedly alleviates inflammation in ANIT rats, potentially treating cholestasis and liver injury through JAK2/STAT3 inhibition and Th17/Treg balance regulation.

Keywords

ANIT / TH17/Treg / Cholestatic liver injury / Xiaohuang Qudan decoction / JAK2/STAT3 / UHPLC-MS/MS

References

[1] Xu JJ, Xu F, Wang W, et al. Paeoniae Radix Rubra can enhance fatty acid β-oxidation and alleviate gut microbiota disorder in α-naphthyl isothiocyanate induced cholestatic model rats. Front Pharmacol. 2022; 13(5):1002922. https://doi.org/10.3389/fphar.2022.1002922.

[2] Colares JR, Hartmann RM, Schemitt EG, et al. Melatonin prevents oxidative stress, inflammatory activity, and DNA damage in cirrhotic rats. World J Gastroenterol. 2022; 28(3):348-364. https://doi.org/10.3748/wjg.v28.i3.348.

[3] Ferreira-Silva M, Faria-Silva C, Carvalheiro MC, et al. Quercetin liposomal nanoformulation for ischemia and reperfusion injury treatment. Pharmaceutics. 2022; 14(1):.15513. https://doi.org/10.3390/pharmaceutics14010104.

[4] Zollner G, Trauner M.Mechanisms of cholestasis. Clin Liver Dis. 2008; 12(1):1-26,vii. https://doi.org/10.1016/j.cld.2007.11.010.

[5] Amirneni S, Haep N, Gad MA, et al. Molecular overview of progressive familial intrahepatic cholestasis. World J Gastroenterol. 2020; 26(47):7470-7484. https://doi.org/10.3748/wjg.v26.i47.7470.

[6] Perez-Cuadrado-Robles E, Becq A, Rahmi G. Choosing the optimal stent in malignant extrahepatic biliary obstruction: What is the most pertinent outcome?. Dig Endosc. 2022; 34(5):952-954. https://doi.org/10.1111/den.14332.

[7] Xu J, Kausalya PJ, Van Hul N, et al. Protective functions of ZO-2/Tjp2 expressed in hepatocytes and cholangiocytes against liver injury and cholestasis. Gastroenterology. 2021; 160(6):2103-2118. https://doi.org/10.1053/j.gastro.2021.01.027.

[8] Chiang JY.Bile acid metabolism and signaling. Compr Physiol. 2013; 3(3):1191-1212. https://doi.org/10.1002/cphy.c120023.

[9] Li M, Cai SY, Boyer JL. Mechanisms of bile acid mediated inflammation in the liver. Mol Aspects Med. 2017; 56:45-53. https://doi.org/10.1016/j.mam.2017.06.001.

[10] Shi T, Malik A, Yang Vom Hofe A, et al. Farnesoid X receptor antagonizes macrophage-dependent licensing of effector T lymphocytes and progression of sclerosing cholangitis. Sci Transl Med. 2022; 14(675):eabi4354. https://doi.org/10.1126/scitranslmed.abi4354.

[11] Nguyen K, D'Mello C, Le T, et al. Regulatory T cells suppress sickness behaviour development without altering liver injury in cholestatic mice. J Hepatol. 2012; 56(3):626-631. https://doi.org/10.1016/j.jhep.2011.09.014.

[12] Zhong YM, Wu XR, Wang Q, et al. Changes in peripheral blood 25-hydroxyvitamin D₃, Th17 cells, and CD4⁺ regulatory T cells and their clinical significance in patients with primary biliary cirrhosis. Chin J Hepatol. 2016; 24(11):829-833. https://doi.org/10.3760/cma.j.issn.1007-3418.2016.11.007.

[13] Cichoż-Lach H, Grywalska E, Michalak A, et al. Deviations in peripheral blood cell populations are associated with the stage of primary biliary cholangitis and presence of itching. Arch Immunol Ther Exp (Warsz). 2018; 66(6):443-452. https://doi.org/10.1007/s00005-018-0515-9.

[14] Mulcahy V, Liaskou E, Martin JE, et al. Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells. Hepatol Commun. 2023; 7(4):265-274. https://doi.org/10.1097/HC9.0000000000000110.

[15] Lee CH, Choi Y, Cho H, et al. Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis. Biochem Pharmacol. 2021;183:114312. https://doi.org/10.1016/j.bcp.2020.114312.

[16] Zhang C, Li S, Sun C, et al. Vitexin ameliorates glycochenodeoxycholate-induced hepatocyte injury through SIRT6 and JAK2/STAT3 pathways. Iran J Basic Med Sci. 2021; 24(12):1717-1725. https://doi.org/10.22038/IJBMS.2021.59424.13196.

[17] Zhao R, Dong R, Yang Y, et al. MicroRNA-155 modulates bile duct inflammation by targeting the suppressor of cytokine signaling 1 in biliary atresia. Pediatr Res. 2017; 82(6):1007-1016. https://doi.org/10.1038/pr.2017.87.

[18] Wu SY, Cui SC, Wang L, et al. 18β-Glycyrrhetinic acid protects against α-naphthylisothiocyanate-induced cholestasis through activation of the Sirt1/FXR signaling pathway. Acta Pharmacol Sin. 2018; 39(12):1865-1873. https://doi.org/10.1038/s41401-018-0110-y.

[19] Ferrell JM, Pathak P, Boehme S, et al. Deficiency of both farnesoid X receptor and takeda G protein-coupled receptor 5 exacerbated liver fibrosis in mice. Hepatology. 2019; 70(3):955-970. https://doi.org/10.1002/hep.30513.

[20] Fuchs CD, Paumgartner G, Mlitz V, et al. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2 ^-/- mice by modulating composition, signalling and excretion of faecal bile acids. Gut. 2018; 67(9):1683-1691. https://doi.org/10.1136/gutjnl-2017-314553.

[21] Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015; 148(4):751-761. e758. https://doi.org/10.1053/j.gastro.2014.12.005.

[22] Jang E, Kim BJ, Lee KT, et al. A survey of therapeutic effects of Artemisia capillaris in liver diseases. Evid Based Complement Alternat Med. 2015;2015:728137. https://doi.org/10.1155/2015/728137.

[23] Liu X, Zhao X. Scoparone attenuates hepatic stellate cell activation through inhibiting TGF-β/Smad signaling pathway. Biomed Pharmacother. 2017; 93:57-61. https://doi.org/10.1016/j.biopha.2017.06.006.

[24] Liu W, Tu Z, Liu J, et al. Therapeutic effect of Yinchenhao decoction on cholelithiasis via mucin in the gallbladder and intestine. Fitoterapia. 2024;172:105746. https://doi.org/10.1016/j.fitote.2023.105746.

[25] Zeng M, Li M, Zhang L, et al. Different meridian tropism in three Chinese medicines: Tinglizi (Semen Lepidii Apetali), Yiyiren (Semen Coicis), Cheqianzi (Semen Plantaginis). J Tradit Chin Med. 2019; 39(2):213-220. https://doi.org/10.19852/j.cnki.jtcm.2019.02.009.

[26] Kim BH, Park KS, Chang IM. Elucidation of anti-inflammatory potencies of Eucommia ulmoides bark and Plantago asiatica seeds. J Med Food. 2009; 12(4):764-769. https://doi.org/10.1089/jmf.2008.1239.

[27] Yang PW, Xu PL, Cheng CS, et al. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer. J Ethnopharmacol. 2022;297:115516. https://doi.org/10.1016/j.jep.2022.115516.

[28] Pannee C, Chandhanee I, Wacharee L. Antiinflammatory effects of essential oil from the leaves of Cinnamomum cassia and cinnamaldehyde on lipopolysaccharide-stimulated J774A. 1 cells. J Adv Pharm Technol Res. 2014; 5(4):164-170. https://doi.org/10.4103/2231-4040.143034.

[29] Xie J, Wang YY, Li JX, et al. Effect and mechanism of Poria cocos polysaccharides on myocardial cell apoptosis in rats with myocardial ischemia-reperfusion injury by regulating Rho-ROCK signaling pathway. China J Chin Mater Med. 2023; 48(23):6434-6441. https://doi.org/10.19540/j.cnki.cjcmm.20230816.401.

[30] Huang DF, Xie MY, Yin JY, et al. Immunomodulatory activity of the seeds of Plantago asiatica L. J Ethnopharmacol. 2009; 124(3):493-498. https://doi.org/10.1016/j.jep.2009.05.017.

[31] Zhang W, He J, Zheng D, et al. Immunomodulatory activity and its mechanisms of two polysaccharides from Poria cocos. Molecules. 2023; 29(1):50. https://doi.org/10.3390/molecules29010050.

[32] Zhimin C, Mingyue AO, Yujiao L, et al. Wuzi Yanzong prescription from traditional Chinese medicine for male infertility: a narrative review. J Tradit Chin Med. 2023; 43(2):416-428. https://doi.org/10.19852/j.cnki.jtcm.20221214.001.

[33] Li L. Clinical observation on 11 cases of acute jaundice hepatitis treated with Xiao-Huang-Qu-Dan decoction. J Chengdu Coll Tradit Chin Med. 1984; 14(4):23-24.

[34] Zhou HQ, Liu W, Wang J, et al. Paeoniflorin attenuates ANIT-induced cholestasis by inhibiting apoptosis in vivo via mitochondria-dependent pathway. Biomed Pharmacother. 2017; 89(7):696-704. https://doi.org/10.1016/j.biopha.2017.02.084.

[35] Wei X, Fan X, Feng Z, et al. Ethyl acetate extract of Herpetospermum pedunculosum alleviates α-naphthylisothiocyanate-induced cholestasis by activating the farnesoid x receptor and suppressing oxidative stress and inflammation in rats. Phytomedicine. 2020; 76(4):153257. https://doi.org/10.1016/j.phymed.2020.153257.

[36] Liu J, Liu J, Meng C, et al. Oleanolic acid alleviates ANIT-induced cholestatic liver injury by activating Fxr and Nrf2 pathways to ameliorate disordered bile acids homeostasis. Phytomedicine. 2022; 102(12):154173. https://doi.org/10.1016/j.phymed.2022.154173.

[37] Jia J, Feng L, Ye S, et al. Therapeutic effect of chinese herbal medicine gu-ben-hua-shi (AESS) formula on atopic dermatitis through regulation of yes-associated protein. Front Pharmacol. 2022; 13(14):929580. https://doi.org/10.3389/fphar.2022.929580.

[38] Wu P, Qiao L, Yu H, et al. Arbutin alleviates the liver injury of α-naphthylisothiocyanate-induced cholestasis through farnesoid X receptor activation. Front Cell Dev Biol. 2021; 9(15):758632. https://doi.org/10.3389/fcell.2021.758632.

[39] Khayat MT, Mohammad KA, Mohamed GA, et al. γ-Mangostin abrogates AINT-induced cholestatic liver injury: impact on Nrf2/NF-κB/NLRP3/Caspase-1/IL-1β/GSDMD signalling. Life Sci. 2023; 322(13):121663. https://doi.org/10.1016/j.lfs.2023.121663.

[40] Silva-Veiga FM, Miranda CS, Vasques-Monteiro IML, et al. Peroxisome proliferator-activated receptor-α activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice. World J Gastroenterol. 2022; 28(17):1814-1829. https://doi.org/10.3748/wjg.v28.i17.1814.

[41] Zhan X, Peng W, Wang Z, et al. Polysaccharides from garlic protect against liver injury in DSS-induced inflammatory Bowel disease of mice via suppressing pyroptosis and oxidative damage. Oxid Med Cell Longev. 2022; 20(2):2042163. https://doi.org/10.1155/2022/2042163.

[42] Zhang S, Zhong R, Tang S, et al. Baicalin alleviates short-term lincomycin-induced intestinal and liver injury and inflammation in infant mice. Int J Mol Sci. 2022; 23(11):1542-1554. https://doi.org/10.3390/ijms23116072.

[43] Wang Y, Shi K, Tu J, et al. Atractylenolide III ameliorates bile duct ligation-induced liver fibrosis by inhibiting the PI3K/AKT pathway and regulating glutamine metabolism. Molecules. 2023; 28(14):546814. https://doi.org/10.3390/molecules28145504.

[44] Zhou Y, Zhou Y, Li Y, et al. Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT- and BDL-induced cholestasis. Front Pharmacol. 2022; 13(2):959074. https://doi.org/10.3389/fphar.2022.959074.

[45] Chen J, Vitetta L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications. Int J Mol Sci. 2020; 21(15):13541. https://doi.org/10.3390/ijms21155214.

[46] Bajpai VK, Sonwal S, Hwang SK, et al. Sugiol, a diterpenoid: therapeutic actions and molecular pathways involved. Pharmacol Res. 2021;163:105313. https://doi.org/10.1016/j.phrs.2020.105313.

[47] Hajib A, El Harkaoui S, Choukri H, et al. Apiaceae family an important source of petroselinic fatty acid: abundance, biosynthesis, chemistry, and biological proprieties. Biomolecules. 2023; 13(11):368-377. https://doi.org/10.3390/biom13111675.

[48] Yang K, Wu B, Wei W, et al. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Int Immunopharmacol. 2023; 118(7):110082. https://doi.org/10.1016/j.intimp.2023.110082.

[49] Liu X, Wang M, Song Y, et al. Kukoamine A inhibits C-C motif chemokine receptor 5 to attenuate lipopolysaccharide-induced lung injury. Drug Dev Res. 2022; 83(6):1455-1466. https://doi.org/10.1002/ddr.21975.

[50] Wang F, Zhang X, Liu W, et al. Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK/STAT pathway. Cell Mol Gastroenterol Hepatol. 2022; 13(1):257-274. https://doi.org/10.1016/j.jcmgh.2021.08.019.

[51] Li Z, Hao E, Cao R, et al. Analysis on internal mechanism of zedoary turmeric in treatment of liver cancer based on pharmacodynamic substances and pharmacodynamic groups. Chin Herb Med. 2022; 14(4):479-493. https://doi.org/10.1016/j.chmed.2022.06.007.

[52] Kohjima M, Enjoji M, Yada R, et al. Pathophysiological analysis of primary biliary cirrhosis focusing on choline/phospholipid metabolism. Liver Int. 2015; 35(3):1095-1102. https://doi.org/10.1111/liv.12526.

[53] Li G, Zhou F, Chen Y, et al. Kukoamine A attenuates insulin resistance and fatty liver through downregulation of Srebp-1c. Biomed Pharmacother. 2017; 89(15):536-543. https://doi.org/10.1016/j.biopha.2017.02.024.

[54] Mehedint MG, Zeisel SH. Choline’s role in maintaining liver function: new evidence for epigenetic mechanisms. Curr Opin Clin Nutr Metab Care. 2013; 16(3):339-345. https://doi.org/10.1097/MCO.0b013e3283600d46.

[55] Haraguchi H, Ishikawa H, Kubo I. Antioxidative action of diterpenoids from Podocarpus nagi. Planta Med. 1997; 63(3):213-215. https://doi.org/10.1055/s-2006-957655.

[56] Watafua M, Ejiofor JI, Musa A, et al. Acacia sieberiana (Fabaceae) attenuates paracetamol and bile duct ligation-induced hepatotoxicity via modulation of biochemical and oxidative stress biomarkers. Front Pharmacol. 2022; 13(8):959661. https://doi.org/10.3389/fphar.2022.959661.

[57] Lew LC, Hor YY, Jaafar MH, et al. Lactobacillus strains alleviated hyperlipidemia and liver steatosis in aging rats via activation of AMPK. Int J Mol Sci. 2020; 21(16):425-436. https://doi.org/10.3390/ijms21165872.

[58] De Silva NMG, Borges MC, Hingorani AD, et al. Liver function and risk of type 2 diabetes: bidirectional mendelian randomization study. Diabetes. 2019; 68(8):1681-1691. https://doi.org/10.2337/db18-1048.

[59] Gerussi A, Bernasconi DP, O'Donnell SE, et al. Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis. Clin Gastroenterol Hepatol. 2021; 19(8):1688-1697. e1614. https://doi.org/10.1016/j.cgh.2020.08.006.

[60] Mathur D, Morgan M, McKenzie J, et al. Intrahepatic cholestasis of pregnancy: dilemma in diagnosis and management. J Matern Fetal Neonatal Med. 2022; 35(25):8975-8981. https://doi.org/10.1080/14767058.2021.2008896.

[61] Abrigo J, Olguín H, Gutierrez D, et al. Bile acids induce alterations in mitochondrial function in skeletal muscle fibers. Antioxidants (Basel). 2022; 11(9):574561. https://doi.org/10.3390/antiox11091706.

[62] Hsu PW, Liao PC, Kao YH, et al. The mutation hotspots at UGT1A locus may be associated with Gilbert’s syndrome affecting the Taiwanese population. Int J Mol Sci. 2022; 23(20):487542. https://doi.org/10.3390/ijms232012709.

[63] Zhang C, Jin H, Wang Y, et al. Critical role of OX40 in drug-induced acute liver injury. Br J Pharmacol. 2020; 177(14):3183-3196. https://doi.org/10.1111/bph.15041.

[64] Ghonem NS, Assis DN, Boyer JL.Fibrates and cholestasis. Hepatology. 2015; 62(2):635-643. https://doi.org/10.1002/hep.27744.

[65] Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. Clin Gastroenterol Hepatol. 2023; 21(8):2076-2087. https://doi.org/10.1016/j.cgh.2023.02.005.

[66] Chang J, Lan T, Li C, et al. Activation of Slit2-Robo1 signaling promotes liver fibrosis. J Hepatol. 2015; 63(6):1413-1420. https://doi.org/10.1016/j.jhep.2015.07.033.

[67] He X, Kang K, Pan D, et al. FTY720 attenuates APAP-induced liver injury via the JAK2/STAT3 signaling pathway. Int J Mol Med. 2022; 49(5):789-799. https://doi.org/10.3892/ijmm.2022.5123.

[68] Chen Y, Hou C, Yang N, et al. Regulatory effect of JAK2/STAT3 on the immune function of endotoxin-tolerant dendritic cells and its involvement in acute liver failure. J Clin Transl Hepatol. 2022; 10(5):879-890. https://doi.org/10.14218/JCTH.2021.00175.

[69] O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015; 66(5):311-328. https://doi.org/10.1146/annurev-med-051113-024537.

[70] Piao X, Sui X, Liu B, et al. Picroside II improves severe acute pancreatitis-induced hepatocellular injury in rats by affecting JAK2/STAT3 phosphorylation signaling. Biomed Res Int. 2021; 20(12):9945149. https://doi.org/10.1155/2021/9945149.

[71] Chen Z, Wu Y, Wang B, et al. Intrahepatic cholestasis induced by α-naphthylisothiocyanate can cause gut-liver axis disorders. Environ Toxicol Pharmacol. 2021; 86(16):103672. https://doi.org/10.1016/j.etap.2021.103672.

[72] Liu Y, Chen K, Li F, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice. Hepatology. 2020; 71(6):2050-2066. https://doi.org/10.1002/hep.30975.

[73] Isaacs-Ten A, Echeandia M, Moreno-Gonzalez M, et al. Intestinal microbiome-macrophage crosstalk contributes to cholestatic liver disease by promoting intestinal permeability in mice. Hepatology. 2020; 72(6):2090-2108. https://doi.org/10.1002/hep.31228.

[74] Sun J, Zhang J, Wang X, et al. Gut-liver crosstalk in sepsis-induced liver injury. Crit Care. 2020; 24(1):614. https://doi.org/10.1186/s13054-020-03327-1.

[75] Bokemeyer A, Lenze F, Stoica V, et al. Digital single-operator video cholangioscopy improves endoscopic management in patients with primary sclerosing cholangitis-a retrospective observational study. World J Gastroenterol. 2022; 28(20):2201-2213. https://doi.org/10.3748/wjg.v28.i20.2201.

[76] Li M, Zhang X, Lu Y, et al. The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines. Cell Death Dis. 2020; 11(1):31. https://doi.org/10.1038/s41419-020-2225-6.

[77] Zeng L, Yang T, Yang K, et al. Efficacy and safety of curcumin and Curcuma longa extract in the treatment of arthritis: a systematic review and meta-analysis of randomized controlled trial. Front Immunol. 2022;13:891822. https://doi.org/10.3389/fimmu.2022.891822.

[78] Tsiogkas SG, Mavropoulos A, Dardiotis E, et al. A sharp decrease of Th17, CXCR3⁺-Th17, and Th17.1 in peripheral blood is associated with an early anti-IL-17-mediated clinical remission in psoriasis. Clin Exp Immunol. 2022; 210(1):79-89. https://doi.org/10.1093/cei/uxac069.

[79] Vujovic A, Isakovic AM, Misirlic-Dencic S, et al. IL-23/IL-17 axis in chronic hepatitis C and non-alcoholic steatohepatitis-new insight into immunohepatotoxicity of different chronic liver diseases. Int J Mol Sci. 2023; 24(15):685-694. https://doi.org/10.3390/ijms241512483.

[80] Jia H, Chen J, Zhang X, et al. IL-17A produced by invariant natural killer T cells and CD3⁺CD56⁺ αGalcer-CD1d tetramer-T cells promote liver fibrosis in patients with primary biliary cholangitis. J Leukoc Biol. 2022; 112(5):1079-1087. https://doi.org/10.1002/JLB.2A0622-586RRRR.

[81] Trivedi PJ, Adams DH. Chemokines and chemokine receptors as therapeutic targets in inflammatory Bowel disease; pitfalls and promise. J Crohns Colitis. 2018; 12(12):1508. https://doi.org/10.1093/ecco-jcc/jjy130.

[82] Hao LR, Li XF, Gao C, et al. Th17/Treg cell level and clinical characteristics of peripheral blood of patients with Sjogren’s syndrome complicated with primary biliary cirrhosis. Medicine (Baltimore). 2019; 98(24):e15952. https://doi.org/10.1097/MD.0000000000015952.

[83] Liu J, Fei Y, Zhou T, et al. Bile acids impair vaccine response in children with biliary atresia. Front Immunol. 2021; 12(3):642546. https://doi.org/10.3389/fimmu.2021.642546.

[84] Sun M, Wu W, Liu Z, et al. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J Gastroenterol. 2017; 52(1):1-8. https://doi.org/10.1007/s00535-016-1242-9.

[85] Yang M, Zhang Q, Taha R, et al. Polysaccharide from Atractylodes macrocephala Koidz. ameliorates DSS-induced colitis in mice by regulating the Th17/Treg cell balance. Front Immunol. 2022; 13(6):1021695. https://doi.org/10.3389/fimmu.2022.1021695.

[86] Zhao Y, Luan H, Jiang H, et al. Gegen Qinlian decoction relieved DSS-induced ulcerative colitis in mice by modulating Th17/Treg cell homeostasis via suppressing IL-6/JAK2/STAT3 signaling. Phytomedicine. 2021; 84(7):153519. https://doi.org/10.1016/j.phymed.2021.153519.

[87] Jin C, Gao BB, Zhou WJ, et al. Hydroxychloroquine attenuates autoimmune hepatitis by suppressing the interaction of GRK2 with PI3K in T lymphocytes. Front Pharmacol. 2022; 13(12):972397. https://doi.org/10.3389/fphar.2022.972397.

[88] Nazmy EA, Helal MG, Said E. Nifuroxazide mitigates cholestatic liver injury by synergistic inhibition of Il-6/β-catenin signaling and enhancement of BSEP and MDRP₂ expression. Int Immunopharmacol. 2021; 99(5):107931. https://doi.org/10.1016/j.intimp.2021.107931.

[89] Zhang M, Wu W, Huang C, et al. Shuxie-1 decoction alleviated CUMS -induced liver injury via IL-6/JAK2/STAT3 signaling. Front Pharmacol. 2022; 13(3):848355. https://doi.org/10.3389/fphar.2022.848355.

[90] Jie XL, Luo ZR, Yu J, et al. Pi-Pa-Run-Fei-Tang alleviates lung injury by modulating IL-6/JAK2/STAT3/IL-17 and PI3K/AKT/NF-κB signaling pathway and balancing Th17 and Treg in murine model of OVA-induced asthma. J Ethnopharmacol. 2023; 317(12):116719. https://doi.org/10.1016/j.jep.2023.116719.

[91] Hu J, Ying H, Zheng Y, et al. Alanyl-glutamine protects against lipopolysaccharide-induced liver injury in mice via alleviating oxidative stress, inhibiting inflammation, and regulating autophagy. Antioxidants (Basel). 2022; 11(6):3214-3225. https://doi.org/10.3390/antiox11061070.

[92] Feng L, Chen Y, Xu K, et al. Cholesterol-induced leucine aminopeptidase 3 (LAP3) upregulation inhibits cell autophagy in pathogenesis of NAFLD. Aging (Albany NY). 2022; 14(7):3259-3275. https://doi.org/10.18632/aging.204011.

[93] Ruart M, Chavarria L, Campreciós G, et al. Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. J Hepatol. 2019; 70(3):458-469. https://doi.org/10.1016/j.jhep.2018.10.015.

[94] Gao J, Wei B, de Assuncao TM, et al. Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis. J Hepatol. 2020; 73(5):1144-1154. https://doi.org/10.1016/j.jhep.2020.04.044.

[95] Xu J, Zhao X, Jiang X, et al. Tubastatin A improves post-resuscitation myocardial dysfunction by inhibiting NLRP3-mediated pyroptosis through enhancing transcription factor EB signaling. J Am Heart Assoc. 2022; 11(7):e024205. https://doi.org/10.1161/JAHA.121.024205.

[96] Deretic V. Autophagy in inflammation, infection, and immunometabolism. Immunity. 2021; 54(3):437-453. https://doi.org/10.1016/j.immuni.2021.01.018.